CULLINAN THERAPEUTICS, INC.

Analyst Reco. Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq Other stock markets 21:00:00 02/07/2024 BST			5-day change	1st Jan Change
16.31 ^USD	-2.51%		-0.67%	+60.06%

06-02	Transcript : Cullinan Therapeutics, Inc. - Special Call
06-01	Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing	05-09	MT
CULLINAN ONCOLOGY : Morgan Stanley Adjusts Cullinan Oncology's Price Target to $43 From $40, Maintains Overweight Rating	07/06/21	MT
CULLINAN ONCOLOGY : HC Wainwright Adjusts Cullinan Management PT to $55 From $48, Maintains Buy Rating	04/06/21	MT
CULLINAN ONCOLOGY : SVB Leerink Adjusts Price Target on Cullinan Management to $54 From $48, Maintains Outperform Rating	04/06/21	MT
CULLINAN ONCOLOGY : Morgan Stanley Upgrades Cullinan Management to Overweight from Equalweight, Sets $40 Price Target	27/04/21	MT
CULLINAN ONCOLOGY : Morgan Stanley Adjusts Price Target on Cullinan Management to $40 From $38, Maintains Equal-Weight Rating	19/04/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer